Synthesis of novel indole-thiazolidinone hybrid structures as promising scaffold with anticancer potential.

A series of novel indole-azolidinone hybrids has been synthesized via Knoevenagel reaction of 5-fluoro-3-formyl-1H-indole-2-carboxylic acid methyl ester and some azolidinones differing in heteroatoms in positions 1, 2 and 4. Their anticancer activity in vitro was screened towards MCF-7 (breast cancer), HCT116 (colon cancer), HepG2 (hepatoma), HeLa (cervical cancer), A549 (lung cancer), WM793 (melanoma) and THP-1 (leukemia) cell lines, and a highly active 5-fluoro-3-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-1H-indole-2-carboxylic acid methyl ester (3a) was identified and subjected to in-depth investigation of cytotoxicity mechanisms. This compound was found to possess the highest cytotoxic action towards tumor cells comparing with the action of other derivatives (1, 3b, 3c, 3d, 3e). Compound 3a exhibited toxicity toward MCF-7, HCT116, and A549, HepG2 cancer cells, while the non-malignant cells (human keratinocytes of HaCaT line and murine embryonic fibroblasts of Balb/c 3T3 line) possessed moderate sensitivity to it. The compound 3a induced apoptosis in studied tumor cells via caspase 3-, PARP1-, and Bax-dependent mechanisms; however, it did not affect the G1/S transition in HepG2 cells. The compound 3a impaired nuclear DNA in HepG2, HCT116, and MCF-7 cells without intercalating this biomolecule, but much less DNA damage events were induced by 3a in normal Balb/c 3T3 fibroblasts compared with HepG2 carcinoma cells. Thus, 5-fluoro-3-(4-oxo-2-thioxothiazolidin-5-ylidenemethyl)-1H-indole-2-carboxylic acid methyl ester 3a was shown to trigger DNA damage and induce apoptosis of human tumor cells and it might be considered as an anticancer agent perspective for in-depth studies.

Design and evaluation of non-carboxylate 5-arylidene-2-thioxo-4-imidazolidinones as novel non-competitive inhibitors of protein tyrosine phosphatase 1B.

Protein tyrosine phosphatase 1B (PTP1B) acts as a negative regulator of insulin and leptin signalling and is crucially involved in the development of type 2 diabetes mellitus, obesity, cancer and neurodegenerative diseases. Pursuing our efforts to identify PTP1B inhibitors endowed with drug-like properties, we designed and evaluated 3-aryl-5-arylidene-2-thioxo-4-imidazolidinones (7) as a novel class of non-carboxylate PTP1B inhibitors. In agreement with our design, kinetic studies demonstrated that selected compounds 7 act as reversible, non-competitive inhibitors of the target enzyme at low micromolar concentrations. Accordingly, molecular docking experiments suggested that these inhibitors can fit an allosteric site of PTP1B that we previously individuated. Moreover, cellular assays demonstrated that compound 7e acts as a potent insulin-sensitizing agent in human liver HepG2 cells. Taken together, our results showed that these non-competitive PTP1B inhibitors can be considered promising lead compounds aimed to enhance druggability of the target enzyme and identify novel antidiabetic drugs.

Design and synthesis of imidazolidinone derivatives as potent anti-leishmanial agents by bioisosterism.

Bioisosterism is a useful strategy in rational drug design to improve pharmacodynamic and pharmacokinetic properties of lead compounds. Imidazolidinones have been reported as potent kinase inhibitors and antileishmanial agents. In this study, bioisosteres of imidazolidinones (compounds 1-3) were evaluated for their antileishmanial properties. The modified imidazolidinones exhibited potent antileishmanial activity against extracellular as well as intracellular Leishmania donovani parasites in nanomolar concentrations. The selectivity index of these compounds on host cells was found to be more than 1000, emphasizing their specificity toward the parasite. Using SwissTargetPrediction software, we assessed the potential targets of these compounds and found MAPK as the most probable target. To in vitro validate, we developed a novel in vitro kinase assay that mimics the in vivo nature of the functional kinome. Compounds 1-3 displayed specific inhibition of parasite kinase activity accompanied by an increase in intracellular sodium levels in the parasites. This might be the effect of kinase inhibition that regulates sodium homeostasis through Na-ATPases. Finally, the compound-treated parasites underwent apoptosis-like death. This study represents bioisoterism as a novel approach for drug design to establish the structure-activity relationship, which in turn helps to improve the therapeutic activity of lead compounds.

Synthesis of N-H Bearing Imidazolidinones and Dihydroimidazolones Using Aza-Heck Cyclizations.

The synthesis of unsaturated, unprotected imidazolidinones via an aza-Heck reaction is described. This palladium-catalyzed process allows for the cyclization of N-phenoxy ureas onto pendant alkenes. The reaction has broad functional group tolerance, can be applied to complex ring topologies, and can be used to directly prepare mono- and bis-unprotected imidazolidinones. By addition of Bu4 NI, dihydroimidazolones can be accessed from the same starting materials. Improved conditions for preparing unsaturated, unprotected lactams are also reported.

An analysis of the complementary stereoselective alkylations of imidazolidinone derivatives toward α-quaternary proline-based amino amides.

Alkylations of proline-based imidazolidinones are described based on the principle of self-regeneration of stereocenters (SRS), affording high levels of either the cis or trans configured products. Stereoselectivity is dictated solely on the nature of the "temporary" group, where isobutyraldehyde-derived imidazolidinones provide the cis configured products and 1-naphthaldehyde-derived imidazolidinones afford the complementary trans configured products. These stereodivergent products can be readily cleaved to afford both α-alkylated proline enantiomers from readily available L-proline. A series of imidazolidinones were alkylated to investigate the origin of the anti-selectivity. Potential contributions toward the observed anti-selectivity are discussed on the basis of these experiments, suggesting a refined hypothesis for selectivity may be in order.

Imidazolidinones and Imidazolidine-2,4-diones as Antiviral Agents.

Imidazolidinones and imidazolidine-2,4-diones are important classes of heterocyclic compounds that possess potent activities against several viruses such as dengue virus, enterovirus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The first imidazolidinone derivative as an anti-HIV agent was reported in 1996. Imidazolidinones inhibit HIV aspartic protease activity, and also act as CCR5 co-receptor antagonists. Significant effort has been devoted to the design of various imidazolidinone analogues that are active against drug-resistant HIV strains, with fewer side effects. Different scaffolds have been designed through both rational drug design strategies and computer-aided drug design. Imidazolidinones have been found to be potent against HIV, and preclinical studies are currently in progress. There are some reports of imidazolidinones as having both anti-HCV and anti-dengue virus activity, and more research has yet to be done along these lines. These compounds inhibit NS3 serine protease of HCV, and NS2B-NS3 protease of dengue virus. Pyridyl-imidazolidinones possess very specific and potent activity against human enterovirus 71 (EV71) by targeting the EV71 capsid protein VP1, and inhibiting viral adsorption and/or viral RNA uncoating.

Efectos protectores de las proantocianidinas a nivel intestinal frente a estrés termooxidativo por ingestión de aceite de girasol utilizado en fritura / The Origins of Enantioselective Organocatalysis and the 2021 Nobel Prize in Chemistry

Una sociedad avanzada requiere el continuo desarrollo de nuevas moléculas y materiales para su uso como fármacos, productos agroquímicos, producción y almacenaje de energía y múltiples otras aplicaciones. A su vez, este desarrollo requiere el descubrimiento y optimización de nuevos métodos de síntesis. El Premio Nobel de Química de 2021 se concedió a los profesores Benjamin List y David MacMillan “por el desarrollo de la organocatálisis asimétrica”. Se trata de una nueva herramienta en síntesis orgánica enantioselectiva que ha crecido de forma exponencial desde su introducción en 2000 por los galardonados y sirve de alternativa a los métodos tradicionales de catálisis, basados en el uso de enzimas y catalizadores metálicos. (AU)

Any advanced society requires new molecules and materials to be used as drugs, agrochemicals, energy production and storage and countless other applications. This, in turn, requires the development of new methods for synthesis. The 2021 Nobel Prize in Chemistry was awarded to Professors Benjamin List and David MacMillan “for the development of asymmetric organocatalysis”. This is a relatively new tool for enantioselective organic synthesis that has undergone an explosive growth since its introduction in 2000 by the awardees and serves as an alternative to the more traditional catalytic procedures based on the use of enzymes and metal-based catalysts. (AU)

Los orígenes de la organocatálisis enantioselectiva y el premio Nobel de Química de 2021 / The Origins of Enantioselective Organocatalysis and the 2021 Nobel Prize in Chemistry

Una sociedad avanzada requiere el continuo desarrollo de nuevas moléculas y materiales para su uso como fármacos, productos agroquímicos, producción y almacenaje de energía y múltiples otras aplicaciones. A su vez, este desarrollo requiere el descubrimiento y optimización de nuevos métodos de síntesis. El Premio Nobel de Química de 2021 se concedió a los profesores Benjamin List y David MacMillan “por el desarrollo de la organocatálisis asimétrica”. Se trata de una nueva herramienta en síntesis orgánica enantioselectiva que ha crecido de forma exponencial desde su introducción en 2000 por los galardonados y sirve de alternativa a los métodos tradicionales de catálisis, basados en el uso de enzimas y catalizadores metálicos. (AU)

Any advanced society requires new molecules and materials to be used as drugs, agrochemicals, energy production and storage and countless other applications. This, in turn, requires the development of new methods for synthesis. The 2021 Nobel Prize in Chemistry was awarded to Professors Benjamin List and David MacMillan “for the development of asymmetric organocatalysis”. This is a relatively new tool for enantioselective organic synthesis that has undergone an explosive growth since its introduction in 2000 by the awardees and serves as an alternative to the more traditional catalytic procedures based on the use of enzymes and metal-based catalysts. (AU)